SEC Form 4 · accession 0001553878-18-000012
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Maraganore
Officer — Chief Executive Officer · Director
Period of report
Mar 1, 2018
Accepted (ET)
Mar 5, 2018 · 5:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $119.13 | Mar 1, 2018 | A | 52,500 | A | — | Feb 28, 2028 | Common Stock | 52,500 | 52,500 | D |
Explanation of responses
- F1Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2017. The reporting person also received 52,500 options to purchase shares of ALNY common stock that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests.
- F2The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months